Huseyin Yetik1,2, Murat Gunay3, Sarkis Sirop4, Ziya Salihoglu5,6. 1. Cerrahpasa School of Medicine, Istanbul University, Fatih, Istanbul, Turkey. huseyinyetik@gmail.com. 2. Surp Pirgic Armenian Foundation Hospital, Affiliated Hospital of Istanbul University, Zakirbaşı Sokak, 34020, Zeytinburnu, Istanbul, Turkey. huseyinyetik@gmail.com. 3. Turkish Republic Ministry of Health Zeynep Kamil Gynocology and Pediatrics Education and Research Hospital, Uskudar, Istanbul, Turkey. drmurat301@yahoo.com.tr. 4. Surp Pirgic Armenian Foundation Hospital, Affiliated Hospital of Istanbul University, Zakirbaşı Sokak, 34020, Zeytinburnu, Istanbul, Turkey. sarkissirop@yahoo.com. 5. Cerrahpasa School of Medicine, Istanbul University, Fatih, Istanbul, Turkey. zsalihoglu@yahoo.com. 6. Bezmialem Foundation University, Fatih, Istanbul, Turkey. zsalihoglu@yahoo.com.
Abstract
PURPOSE: To study the efficacy of intravitreal bevacizumab (IVB) injection as a single treatment for retinopathy of prematurity (ROP). METHODS: This was a prospective interventional case series study performed in a clinical practice setting; a total of 122 patients including prethreshold (type 1) (n = 79, 152 eyes, six unilateral), threshold (n = 12, 24 eyes), and aggressive posterior (APROP) (n = 31, 62 eyes); cases were included without any randomization or masking. A total of 253 IVB injections, 238 in the first session, 11 in the second session, and four in the third session were performed, and followed up for a mean of 89.155 ± 4.277 (range 82 to 105) weeks of postmenstrual age (PMA). Regression of ROP, maturation of the retina, and associated complications were evaluated. RESULTS: Total regression was achieved in 227/238 eyes (95.4 %) after the first dose injection. The remaining 11 received a second injection, after which an additional seven (234/238; 98.2 %) regressed; after the third injection, the remaining 4 (238/238; 100 %) regressed. Complete retinal vascular maturation was achieved without any significant complications in all of the cases. CONCLUSIONS: IVB injection as monotherapy seems to be a very effective treatment modality for ROP. Based on timely intervention, IVB as a single treatment modality can salvage almost all ROP cases before stage 4.
PURPOSE: To study the efficacy of intravitreal bevacizumab (IVB) injection as a single treatment for retinopathy of prematurity (ROP). METHODS: This was a prospective interventional case series study performed in a clinical practice setting; a total of 122 patients including prethreshold (type 1) (n = 79, 152 eyes, six unilateral), threshold (n = 12, 24 eyes), and aggressive posterior (APROP) (n = 31, 62 eyes); cases were included without any randomization or masking. A total of 253 IVB injections, 238 in the first session, 11 in the second session, and four in the third session were performed, and followed up for a mean of 89.155 ± 4.277 (range 82 to 105) weeks of postmenstrual age (PMA). Regression of ROP, maturation of the retina, and associated complications were evaluated. RESULTS: Total regression was achieved in 227/238 eyes (95.4 %) after the first dose injection. The remaining 11 received a second injection, after which an additional seven (234/238; 98.2 %) regressed; after the third injection, the remaining 4 (238/238; 100 %) regressed. Complete retinal vascular maturation was achieved without any significant complications in all of the cases. CONCLUSIONS: IVB injection as monotherapy seems to be a very effective treatment modality for ROP. Based on timely intervention, IVB as a single treatment modality can salvage almost all ROP cases before stage 4.
Entities:
Keywords:
Anti-VEGF; Bevacizumab; Intravitreal injection; Retinopathy of prematurity (ROP)
Authors: Björn C Harder; Frank C Schlichtenbrede; Stefan von Baltz; Waldemar Jendritza; Bettina Jendritza; Jost B Jonas Journal: Am J Ophthalmol Date: 2013-03-12 Impact factor: 5.258
Authors: Geeta A Lalwani; Audina M Berrocal; Timothy G Murray; Maria Buch; Scott Cardone; Ditte Hess; Rose A Johnson; Carmen A Puliafito Journal: Retina Date: 2008-03 Impact factor: 4.256
Authors: Parag K Shah; Prema Subramanian; Narendran Venkatapathy; Robison Vernon Paul Chan; Michael F Chiang; John Peter Campbell Journal: J AAPOS Date: 2019-09-12 Impact factor: 1.220